O-1602,GPR55激动剂(ab120407)
Key features and details
- Potent, selective GPR55 agonist
- CAS Number: 317321-41-8
30mg/mL - EtOH; 0.5mg/mL - Ethanol:PBS(pH 7.2)(1:1); 30mg/mL - DMSO; 30mg/mL - DMF; Insoluble - PBS (pH 7.2)
- Form / State: Liquid
- Source: Synthetic
概述
-
产品名称
O-1602,GPR55激动剂 -
描述
Potent,selective GPR55激动剂 -
生物学描述
Analog of cannabidiol that is a potent agonist at the GPR55 cannabinoid receptor (EC50 values are 13, >30000 and >30000 nM for GPR55, CB1 and CB2 receptors, respectively). Inhibits mouse osteoclast formation in vitro, stimulates osteoclast polarization and resorption, causes activation of Rho and ERK1/2, and inhibits human neutrophil migration.
-
常规说明
Sold under license from Virginia Commonwealth University. -
CAS编号
317321-41-8 -
化学结构
性能
-
化学名称
5-Methyl-4-((1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-enyl)benzene-1,3-diol
-
分子量
258.36 -
分子式
C17H22O2 -
PubChem识别号
45073499 -
存放说明
Store at -20°C (desiccating conditions). -
溶解度概述
30mg/mL - EtOH; 0.5mg/mL - Ethanol:PBS(pH 7.2)(1:1); 30mg/mL - DMSO; 30mg/mL - DMF; Insoluble - PBS (pH 7.2)
-
处理
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 6 months. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CC(=C)[C@@H]2CCC(C)=C[C@H]2c1c(C)cc(O)cc1O -
来源
Synthetic
-
研究领域
实验方案
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
数据表及文件
-
SDS download
-
Datasheet download
文献 (2)
ab120407 被引用在 2 文献中.
- Fukawa Y et al. IL-1 Generated by Oral Squamous Cell Carcinoma Stimulates Tumor-Induced and RANKL-Induced Osteoclastogenesis: A Possible Mechanism of Bone Resorption Induced by the Infiltration of Oral Squamous Cell Carcinoma. Int J Mol Sci 24:N/A (2022). PubMed: 36614130
- Adinolfi B et al. Anticancer activity of anandamide in human cutaneous melanoma cells. Eur J Pharmacol 718:154-9 (2013). PubMed: 24041928